MYC and B-cell non-Hodgkin lymphoma: Specifically, miR-125a has been reported to reduce malignancy in MM cells by targeting the angiogenesis factors and deubiquitinase USP5 [19], while miR-28-5p controls cell proliferation and MYC activation in B-cell lymphomas [20].